{
  "docId": "019de515-df71-7068-a98d-cc2a99c8892d",
  "docSlug": "c88233ba648814c9f5b65afc1926df6d",
  "documentTitle": "Adagio Therapeutics | Investor Conference Presentation Deck | 11 slides",
  "authorId": "adagio-therapeutics",
  "authorName": "Invivyd",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 11,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de515-df71-7068-a98d-cc2a99c8892d/6",
  "deckHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d",
  "deckJsonHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d.json",
  "deckAnchorHref": "/decks/019de515-df71-7068-a98d-cc2a99c8892d#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.82,
        "x": 0.09,
        "y": 0.79
      },
      "kind": "paragraph",
      "text": "A monoclonal antibody (mAb) therapeutic that offers more robust protection against current variants would be an important addition to the COVID-19 medicine cabinet, especially for vulnerable populations",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "064ea0fd-e35e-4ba6-b572-fe8c5ce99fd6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.38,
        "x": 0.59,
        "y": 0.305
      },
      "kind": "paragraph",
      "text": "4-29% VE against infection with more recent Omicron variants up to 26 weeks from mRNA bivalent booster",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bc17f21-0224-4e34-bc87-e139f1a7d480",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.48,
        "x": 0.035,
        "y": 0.305
      },
      "kind": "paragraph",
      "text": "45.7% VE against symptomatic Omicron B.1.1.529 at ≥10 wks after two doses of the BNT162b2 vaccine followed by a BNT162b2 booster",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "29bce2ca-e657-49a8-b033-ae3b9257c880",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.015,
        "w": 0.47,
        "x": 0.015,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Sources: 1. Andrews N Engl J Med 2022; 2. Shrestha Open Forum Infectious Diseases 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5016a1f4-891f-4232-934f-e13eb1577d38",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.26,
        "w": 0.51,
        "x": 0.035,
        "y": 0.38
      },
      "kind": "table",
      "text": "VE against symptomatic COVID-19 in primarily immunocompetent¹\nMonovalent (BNT162b2)\n2-4 wks after 2nd dose\n≥25 wks after 2nd dose\n2-4 wks after booster\n≥10 wks after booster\nDelta B.1.617.2\n90.9%\n62.7%\n95.1%\n89.9%\nOmicron B.1.1.529\n65.5%\n8.8%\n67.2%\n45.7%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a833c86-23b8-41fe-b8cd-d2f9468f519c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.26,
        "w": 0.38,
        "x": 0.59,
        "y": 0.38
      },
      "kind": "table",
      "text": "VE against SARS-CoV-2 infection in primarily immunocompetent2\nBivalent Booster\nUp to 26 wks from bivalent booster\nOmicron BA.4/5 dominant phase\n29%\nOmicron BQ dominant phase\n20%\nOmicron XBB dominant phase\n4%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9485e9a4-a0d4-4d41-a387-67b7a9247a7d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.91,
        "x": 0.045,
        "y": 0.08
      },
      "kind": "title",
      "text": "EVEN IN PRIMARILY IMMUNOCOMPETENT POPULATIONS, VACCINE EFFECTIVENESS (VE) HAS WANED IN THE FACE OF VIRAL EVOLUTION",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8315bc9-af87-4df6-b8a3-549a16f11ff8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Problem Statement Canvas",
      "slug": "problem-statement-canvas",
      "agent": "Architect",
      "layer": "slide",
      "matchId": "a9a59549-097d-4719-b2ee-d3c35804704a",
      "evidence": "The slide presents a problem statement with data and statistics, highlighting the waning vaccine effectiveness against COVID-19 variants.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 3,
      "beatId": "8b1e41e5-6fc4-4318-a405-3acb902895ca",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Problem",
      "beatSlug": "problem-agitate-solution-problem-identify-pain",
      "evidence": "Slides 3-6 detail the urgent need and complications for immunocompromised people.",
      "position": 0,
      "confidence": 0.9,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 6,
      "from": 5,
      "beatId": "9267716b-6700-4ffc-8701-d4f03cee81cc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 5-6 further emphasize the impaired response to vaccines and waning vaccine effectiveness.",
      "position": 1,
      "confidence": 0.9,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [
    {
      "to": 6,
      "from": 3,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "4ce340fa-5923-4426-abff-c930e25c323b",
      "evidence": "Slides 3-6 emphasize the urgent need and complications, implying significant costs of inaction.",
      "position": 0,
      "objective": "What is the cost of not addressing the urgent need for new therapeutics?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.8,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}